[go: up one dir, main page]

PE20070373A1 - Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6 - Google Patents

Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6

Info

Publication number
PE20070373A1
PE20070373A1 PE2006000985A PE2006000985A PE20070373A1 PE 20070373 A1 PE20070373 A1 PE 20070373A1 PE 2006000985 A PE2006000985 A PE 2006000985A PE 2006000985 A PE2006000985 A PE 2006000985A PE 20070373 A1 PE20070373 A1 PE 20070373A1
Authority
PE
Peru
Prior art keywords
alkyl
naftilsulfonil
integer
hydroxitriptamine
sulfonylindazole
Prior art date
Application number
PE2006000985A
Other languages
English (en)
Inventor
Hassan Mahmoud Elokdah
Alexander Alexei Greenfield
Geraldine Ruth Mcfarlane
Jennifer Rebecca Lo
Albert Jean Robichaud
Cristina Grosanu
Kevin Liu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20070373A1 publication Critical patent/PE20070373A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO SULFONILINDAZOL DE FORMULA (I), DONDE X ES O, S, CO, CH2O, ENTRE OTROS; n ES UN ENTERO DE 0 A 6; R1 ES H, ALQUILO C1-C12, CICLOALQUILO C3-C10, ARILO C6-C20, ENTRE OTROS; R2 ES ALQUILO C1-C12, CICLOALQUILO C3-C10, ARILO C6-C20, ENTRE OTROS; R3 Y R4 SON H O ALQUILO C1-C12, ENTRE OTROS; R5 ES H, ALQUILO C1-C12, ALQUENILO C2-C12, ALQUINILO C2-C6, ENTRE OTROS; R6 ES H O ALQUILO C1-C12; ENTRE OTROS; p ES UN ENTERO DE 0 A 2; R7 ES HALOGENO, CN, ALQUILO C1-C12, ALQUENILO C2-C12, ENTRE OTROS; m ES UN ENTERO DE 0 A 3. SON COMPUESTOS PREFERIDOS: 5-[(1-BUTILPIRROLIDIN-3-IL)OXI]-3-(1-NAFTILSULFONIL)-1H-INDAZOL, 3-(1-NAFTILSULFONIL)-5-[(1-PROPILPIRROLIDIN-3-IL)OXI]-1H-INDAZOL, 5-[(1-ISOPROPILPIRROLIDIN-3-IL)OXI]-3-(1-NAFTILSULFONIL)-1H-INDAZOL, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON LIGANDOS DEL RECEPTOR 5-HIDROXITRIPTAMINA-6 (5-HT6) Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSOS CENTRAL TALES COMO TRASTORNOS MOTORES, NEURODEGENERATIVOS, ANSIEDAD, TRASTORNO COMPULSIVO OBSESIVO, ENTRE OTROS
PE2006000985A 2005-08-15 2006-08-14 Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6 PE20070373A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70831705P 2005-08-15 2005-08-15

Publications (1)

Publication Number Publication Date
PE20070373A1 true PE20070373A1 (es) 2007-04-04

Family

ID=37315656

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000985A PE20070373A1 (es) 2005-08-15 2006-08-14 Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6

Country Status (21)

Country Link
US (1) US7790751B2 (es)
EP (1) EP1915348A1 (es)
JP (1) JP2009504738A (es)
KR (1) KR20080034497A (es)
CN (1) CN101291913A (es)
AR (1) AR056459A1 (es)
AU (1) AU2006291414A1 (es)
BR (1) BRPI0614341A2 (es)
CA (1) CA2619309A1 (es)
CR (1) CR9733A (es)
EC (1) ECSP088176A (es)
GT (1) GT200600374A (es)
IL (1) IL189416A0 (es)
MX (1) MX2008002158A (es)
NO (1) NO20080553L (es)
PE (1) PE20070373A1 (es)
RU (1) RU2008103700A (es)
SV (1) SV2008002653A (es)
TW (1) TW200800913A (es)
WO (1) WO2007032833A1 (es)
ZA (1) ZA200801524B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565872A (en) * 2005-08-15 2011-06-30 Wyeth Corp Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
AR063469A1 (es) * 2006-07-14 2009-01-28 Ranbaxy Lab Ltd Formas polimorficas de ácido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3, 5-dihidroxi-heptanoico, sal hemicalcio, metodos de preparacion de las mismas, una composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades
ATE495153T1 (de) * 2006-11-09 2011-01-15 Hoffmann La Roche Arylsulfonylpyrrolidine als 5-ht6-inhibitoren
EP2158195A1 (en) 2007-05-15 2010-03-03 Wyeth LLC 5- (aminoazacyclyl) -3-sulfonyl-lh- indazoles as 5-hydroxytryptamine- 6 ligands for the treatment of cns disorders
US20090012308A1 (en) * 2007-06-13 2009-01-08 Wyeth Process for the manufacture of benzylsulfonylarenes
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
ES2568262T3 (es) * 2009-04-23 2016-04-28 Abbvie Inc. Moduladores de receptores de 5-HT y sus métodos de uso

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9813926A (pt) * 1997-11-04 2000-09-19 Pfizer Prod Inc Substituição de bioisóstero de catecol por indazol em compostos terapeuticamente ativos
WO2001005758A2 (en) * 1999-07-15 2001-01-25 Nps Allelix Corp. Indoles and indazoles for the treatment of migraine
JP4307073B2 (ja) * 2000-12-22 2009-08-05 ワイス ５−ヒドロキシトリプトアミン−６リガンドとしてのヘテロサイクルインダゾールおよびアザインダゾール化合物
BR0209056A (pt) * 2001-04-20 2004-08-10 Wyeth Corp Derivados de heterociclilóxi-, -tióxi- e -aminobenzazol como ligantes de 5-hidroxitriptamina-6
EA200301143A1 (ru) * 2001-04-20 2004-02-26 Уайт Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
TW200400177A (en) * 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
US7943639B2 (en) * 2002-06-20 2011-05-17 Proximagen Limited Compounds
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
TW200412945A (en) * 2002-10-25 2004-08-01 Upjohn Co Quaternary ammonium compounds
KR20050101551A (ko) * 2003-02-14 2005-10-24 와이어쓰 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴-3-설포닐인다졸
CN1922150A (zh) * 2004-02-27 2007-02-28 霍夫曼-拉罗奇有限公司 吲唑衍生物以及含有它们的药物组合物

Also Published As

Publication number Publication date
JP2009504738A (ja) 2009-02-05
TW200800913A (en) 2008-01-01
ZA200801524B (en) 2010-04-28
ECSP088176A (es) 2008-04-28
GT200600374A (es) 2007-03-29
AU2006291414A1 (en) 2007-03-22
RU2008103700A (ru) 2009-09-27
US7790751B2 (en) 2010-09-07
MX2008002158A (es) 2008-04-19
EP1915348A1 (en) 2008-04-30
BRPI0614341A2 (pt) 2011-03-29
CR9733A (es) 2008-04-02
SV2008002653A (es) 2008-04-11
KR20080034497A (ko) 2008-04-21
AR056459A1 (es) 2007-10-10
NO20080553L (no) 2008-04-23
US20070054896A1 (en) 2007-03-08
CN101291913A (zh) 2008-10-22
IL189416A0 (en) 2008-06-05
WO2007032833A1 (en) 2007-03-22
CA2619309A1 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
ATE487716T1 (de) Indole, 1h-indazole, 1,2-benzisoxazole, 1,2- benzoisothiazole, deren herstellung und verwendungen
PE20030039A1 (es) Derivados de indol con afinidad por el receptor 5-ht6
PE20071245A1 (es) COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs)
PE20080067A1 (es) DERIVADOS DE TRIAZOLOPIRAZINA COMO MODULADORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE HEPATOCITO (c-MET O HGFR)
ATE528304T1 (de) Verbindungen und verfahren zur behandlung von dyslipidämie
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
ATE449604T1 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
PE20090297A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis
MA31858B1 (fr) N-phenyl-bipyrrolidine-carboxamides substitues et utilisation therapeutique de ceux-ci
EA200601785A1 (ru) Соединения и способы лечения дислипидемии
ATE360631T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
PE20081409A1 (es) Antagonistas del receptor de progesterona
CY1112391T1 (el) Υποκατεστημενες ν-φαινυλ-διπυρρολιδινη ουριες και θεραπευτικες χρησεις αυτων
ATE530541T1 (de) Substituierte heteroarylpiperidinderivate als modulatoren des melanocortin-4-rezeptors
PE20070373A1 (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
PE20040828A1 (es) Benzoxazinonas como modulares de 5-hidroxitriptamina (5-ht)
BRPI0519292A2 (pt) compostos orgÂnicos
EA201070495A1 (ru) МОДУЛЯТОРЫ АКТИВНОСТИ γ-СЕКРЕТАЗЫ ИЗ ГРУППЫ ПИПЕРИДИНИЛА И ПИПЕРАЗИНИЛА
PE20090953A1 (es) Sulfonas ciclicas sustituidas por amino-bencilo utiles como inhibidores de bace
ATE484502T1 (de) Neue verbindungen
DE602006014305D1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
AR058760A1 (es) Derivados de aril -isoxasol -4-il- imidazol
ATE388712T1 (de) 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h- chinazolin-2-on-derivate und die jeweiligen 1h- benzo(1,2,6)thiadiazin-2,2-dioxid und 1,4-dihydro-benzo(d)(1,3)oxazin-2-on-derivate als modulatoren des 5-hydroxytryptamin-rezeptors (5-ht) zur behandlung von erkrankungen des zentralen nervensystems
DE502005006955D1 (de) N-(phenyl-oxazol-4-ylmethoxymethyl)-cyclohexyl-bernsteinsäureamid derivate und verwandte verbindungen als ppar-liganden (peroxisomen-proliferatoren-aktivierte rezeptoren) zur behandlung von hyperlipidämie und diabetes

Legal Events

Date Code Title Description
FX Voluntary withdrawal